ABSTRACT
Patients with systemic lupus erythematosus (SLE, lupus) have a markedly better survival rate today than they did 50 years ago, but they face a greater risk of cancer, cardiovascular disease, and osteoporosis at early ages. With better understanding of the immunological mechanisms of the disease, new avenues of therapy are emerging.
Footnotes
↵* Dr. Manzi has disclosed that she serves on advisory boards for Abbot, Aspreva, Bristol-Myers Squibb, Centocor, Genentech, Genelabs, and Genzyme corporations, and the US Food and Drug Administration; has served as a consultant for Cellatope and StageMark corporations, holds intellectual property rights to several current and pending patents; and has received grant or research support from Amgen, Aspreva, Bristol-Myers Squibb, Genelabs, Genentech, Human Genome Sciences, and Immunomedics corporations.
- Copyright © 2009 The Cleveland Clinic Foundation. All Rights Reserved.
